C.R. Bard (NYSE: BCR) and Sientra (NASDAQ:SIEN) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, institutional ownership, analyst recommendations, earnings, profitability, valuation and dividends.
This is a summary of current ratings and target prices for C.R. Bard and Sientra, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
C.R. Bard currently has a consensus target price of $295.43, suggesting a potential downside of 11.05%. Sientra has a consensus target price of $13.75, suggesting a potential upside of 6.26%. Given Sientra’s stronger consensus rating and higher probable upside, analysts plainly believe Sientra is more favorable than C.R. Bard.
Risk & Volatility